Success Metrics

Completion Rate

0%(0/1)

Active Trials

1(33%)

Terminated

1(33%)

Phase Distribution

Ph phase_1

33%

Ph phase_2

33%

Ph not_applicable

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Terminated(1)

Other(1)

Detailed Status

unknown1

Terminated1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

N/A1 (33.3%)

Trials by Status

unknown133%

terminated133%

recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingphase_2

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

NCT04812366

terminatedphase_1

PK and Dose Escalation and Expansion Study of DST-2970

NCT04291664

unknownnot_applicable

Vestibular Prognosis Assessment of ISSNHL With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids

NCT03974867

Clinical Trials (3)

Showing 3 of 3 trials

NCT04812366Phase 2

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Recruiting

NCT04291664Phase 1

PK and Dose Escalation and Expansion Study of DST-2970

Terminated

NCT03974867Not Applicable

Vestibular Prognosis Assessment of ISSNHL With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids

Unknown

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3